126 related articles for article (PubMed ID: 15552190)
1. Out of sight. Pharmaceutical industry temporarily replaces hospitals as target.
McLaughlin N
Mod Healthc; 2004 Oct; 34(42):26. PubMed ID: 15552190
[No Abstract] [Full Text] [Related]
2. Under surveillance.
Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
[No Abstract] [Full Text] [Related]
3. Drug pullout. Massive recall of Vioxx poses logistical problems.
Becker C
Mod Healthc; 2004 Oct; 34(42):17. PubMed ID: 15552189
[No Abstract] [Full Text] [Related]
4. Rofecoxib, Merck, and the FDA.
Villalba L; Witter J
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
[No Abstract] [Full Text] [Related]
5. The politics of therapeutics.
Somberg J
Am J Ther; 2004; 11(6):422. PubMed ID: 15543080
[No Abstract] [Full Text] [Related]
6. COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
Fendrick AM
Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263
[No Abstract] [Full Text] [Related]
7. Merck's recall of rofecoxib--a strategic perspective.
Oberholzer-Gee F; Inamdar SN
N Engl J Med; 2004 Nov; 351(21):2147-9. PubMed ID: 15548771
[No Abstract] [Full Text] [Related]
8. The withdrawal of rofecoxib.
Arellano FM
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
[No Abstract] [Full Text] [Related]
9. When doses disappear. Flu shot shortage sheds light on drug supply chain.
Becker C
Mod Healthc; 2004 Oct; 34(42):16. PubMed ID: 15552188
[No Abstract] [Full Text] [Related]
10. How to avoid future Vioxx-type scandals.
Prescrire Int; 2005 Jun; 14(77):115-7. PubMed ID: 15984108
[TBL] [Abstract][Full Text] [Related]
11. Vioxx's history and the need for better procedures and better testing.
Gilhooley M
Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
[No Abstract] [Full Text] [Related]
12. Evaluating drug effects in the post-Vioxx world: there must be a better way.
Avorn J
Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
[No Abstract] [Full Text] [Related]
13. Cyclooxygenase-2 inhibitors and cardiovascular risk.
Smith ER
Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
[No Abstract] [Full Text] [Related]
14. The Vioxx debacle revisited.
Mohapatra PR; Janmeja AK
Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
[No Abstract] [Full Text] [Related]
15. Vioxx, pharmacovigilance, flu vaccine, and the "prepared mind".
Lampton L
J Miss State Med Assoc; 2004 Nov; 45(11):333-5. PubMed ID: 15624631
[No Abstract] [Full Text] [Related]
16. What happened to the coxibs on the way to the cardiologist?
Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326
[No Abstract] [Full Text] [Related]
17. Some key points emerging from the COX-2 controversy.
Urquhart J
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):145-7. PubMed ID: 15654723
[No Abstract] [Full Text] [Related]
18. Painkiller in the dock.
Nature; 2005 Jul; 436(7050):459. PubMed ID: 16049447
[No Abstract] [Full Text] [Related]
19. Balancing risks and benefits in pain medicine: wither Vioxx.
Gallagher RM
Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
[No Abstract] [Full Text] [Related]
20. The Vioxx debacle revisited.
Good CB; Kelley CL
Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
